AVROBIO, Inc., a leader in lentiviral-based gene therapies, is a clinical stage company developing disruptive therapies that have the potential to transform patients’ lives in a single dose.

Stock Quote

Press Releases
October 4, 2018
AVROBIO, Inc. to Present at Chardan's 2nd Annual Genetic Medicines Conference
CAMBRIDGE, Mass. , Oct. 04, 2018 (GLOBE NEWSWIRE) -- AVROBIO, Inc . (NASDAQ:AVRO) (the “Company”), a Phase 2 clinical-stage gene therapy company developing gene therapies to potentially cure rare diseases with a single dose, today announced that Geoff MacKay , President and CEO of AVROBIO , will